Get the Stockscreener App
3.90
9.30%
-0.40
After Hours:
3.98
0.08
+2.05%
Enveric Biosciences Inc stock is traded at $3.90, with a volume of 1.44M.
It is down -9.30% in the last 24 hours and down -20.34% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
See More
Previous Close:
$4.30
Open:
$4.28
24h Volume:
1.44M
Relative Volume:
26.36
Market Cap:
$2.70M
Revenue:
-
Net Income/Loss:
$-15.08M
P/E Ratio:
-0.6075
EPS:
-6.42
Net Cash Flow:
$-11.56M
1W Performance:
-21.92%
1M Performance:
-20.34%
6M Performance:
-55.28%
1Y Performance:
-67.50%
1-Day Range:
$3.90
$4.83
1-Week Range:
$3.8805
$5.0985
52-Week Range:
$3.8805
$43.80
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
239-302-1707
Address
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Compare ENVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
3.90 | 2.70M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office - BioSpace
Enveric Passes Key Milestone on Patent Path for Mental-Health Treatment - MarketWatch
Enveric Biosciences stock hits 52-week low at $0.29 By Investing.com - Investing.com South Africa
Enveric Biosciences stock hits 52-week low at $0.29 - MSN
Jay Pharma Inc. Announces Appointment of Sara Dakar as Vice President, Product Development - Marketscreener.com
AMERI Holdings, Inc. Announces Executive Changes -April 08, 2019 at 08:00 am EDT - Marketscreener.com
AMERI Holdings, Inc. Announces Board Changes -December 12, 2018 at 06:59 am EST - Marketscreener.com
R. James Woolsey Joins AMERI Holdings as Strategy Consultant -January 27, 2020 at 08:00 am EST - Marketscreener.com
Ameri Holdings, Inc. Approves Director Changes -August 17, 2018 at 08:00 am EDT - Marketscreener.com
Ameri Holdings, Inc. Announces Board Changes -April 02, 2019 at 04:01 pm EDT - Marketscreener.com
Robert Wilkins Joins Jay Pharma as Chief Medical Officer -July 29, 2020 at 09:00 am EDT - Marketscreener.com
Enveric Biosciences Appoints Arash Asher to Scientific Advisory Board -May 12, 2021 at 07:30 am EDT - Marketscreener.com
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders - Marketscreener.com
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally - Marketscreener.com
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Announces 1-for-15 Reverse Stock Split By Investing.com - Investing.com UK
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025” - BioSpace
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8 - Business Wire
Enveric Biosciences CEO to Present Future of Psychedelics Vision at Major JP Morgan Week Events - StockTitan
Enveric Biosciences to Release Investor Presentation - TipRanks
ENVB Stock Touches 52-Week Low at $0.3 Amid Market Challenges - Investing.com Nigeria
Enveric Biosciences (NASDAQ:ENVB) Shares Down 4.6% – Here’s Why - Defense World
Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives - Microdose Psychedelic Insights
Enveric Biosciences secures patents for neuroplasticity drugs By Investing.com - Investing.com Canada
Enveric Biosciences Expands Patent Portfolio for Novel Psilocybin Compounds - StockTitan
Enveric advances neuroplastogen EB-003 through PK studies - BioWorld Online
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results - Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior - Business Wire
Enveric Biosciences faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria
Enveric Biosciences faces potential Nasdaq delisting - Investing.com India
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders - Benzinga
atai Life Sciences and Enveric Biosciences Report Q3 2024 Results - Microdose Psychedelic Insights
Enveric Biosciences narrows net loss, advances lead drug candidate - Green Market Report
Enveric Biosciences Inc (ENVB) Quarterly 10-Q Report - Quartzy
Enveric Biosciences Narrows Q3 Loss, Advances Mental Health Drug Development | ENVB Stock News - StockTitan
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results - Business Wire
Enveric Biosciences licenses drug candidate to MycoMedica By Investing.com - Investing.com Australia
Enveric and MycoMedica’s New Licensing Agreement Marks a Strategic Shift in Mental Health Treatment - Microdose Psychedelic Insights
Enveric Biosciences licenses drug candidate to MycoMedica - Investing.com India
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - BioSpace
Enveric inks $62M licensing deal for psilocin prodrug - Green Market Report
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal - Benzinga
Enveric Biosciences (NASDAQ:ENVB) Trading 1.1% Higher – Time to Buy? - Defense World
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):